We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.
Provisional interim result of the public tender offer of Samsung Biologics Co., Ltd.
13 Oct 2026 - Baar, Switzerland, 13 October 2026 – Samsung Biologics Co., Ltd. (“Samsung Biologics”), through its direct subsidiary Samsung Peptide AG (“Samsung Peptide”), today published the provisional interim […]
Read morePolyPeptide publishes the invitation to its extraordinary general meeting of shareholders on 26 October 2026
2 Oct 2026 - Baar, 2 October 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, published the invitation to its extraordinary general […]
Read moreSamsung Peptide AG publishes offer prospectus for public tender offer for PolyPeptide Group AG
31 Aug 2026 - Baar, 31 August 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced that Samsung Peptide AG, a […]
Read morePolyPeptide delivers +42% growth in H1 2026 and improved EBITDA margin; 2026 full-year guidance updated, now expecting 25-30% revenue growth and high-teens EBITDA margin
13 Aug 2026 - Baar, 13 August 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced its H1 2026 results, updated […]
Read moreSamsung Biologics announces tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share
20 Jul 2026 - Baar, 20 July 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced Samsung Biologics’ tender offer to […]
Read morePolyPeptide Group AG takes note of market rumors and speculation
14 Apr 2026 - Baar, 14 April 2026 – PolyPeptide Group AG (SIX: PPGN) (“PolyPeptide” or the “Company”), a specialized global CDMO for peptide-based active pharmaceutical ingredients, takes note of […]
Read morePolyPeptide delivers strong revenue growth and marked improvement in profitability
12 Mar 2026 - Baar, 12 March 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced its annual results for 2025 […]
Read morePolyPeptide successfully closes financial year 2025 with strong revenue growth and marked improvement in profitability
19 Jan 2026 - Baar, 19 January 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced the successful closing of its […]
Read morePolyPeptide delivers +24% growth in H1 2025, successful ramp-up at its Belgian site, 2025 full-year guidance revised towards the upper end of the range
12 Aug 2025 - Baar, 12 August 2025 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced its results for H1 2025, […]
Read more